Using fusion proteins to trigger immune cells and suppress allergic processes

[Joachim]

In the search for effective and safe therapeutics for hyposensitization, colleagues at the Paul-Ehrlich-Institut and the Justus Liebig University in Giessen investigated the effect of the birch pollen allergen-containing fusion protein rFlaA:Betv1 on B cells (specific immune cells). rFlaA:Betv1 leads to the differentiation of B cells into regulatory cells. These regulatory cells produce antibodies and messenger substances (interleukins) that counteract allergic reactions. This is one of the findings that make fusion proteins promising candidates for allergen-specific immunotherapy (AIT). Allergy reports on the results of this study in its online edition from October 4, 2022.

Link naar het originele artikel